Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.50 |
| ▸ | ENPP2 | Q13822 | 3/20 | 0.41 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 2/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
| ▸ | CA1 | P00915 | 1/20 | 0.36 |
| ▸ | CA2 | P00918 | 1/20 | 0.36 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.36 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.36 |
| ▸ | ORAI1 | Q96D31 | 1/20 | 0.35 |
| ▸ | ORAI2 | Q96SN7 | 1/20 | 0.35 |
| ▸ | ORAI3 | Q9BRQ5 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29468918 | 1.00 | TSHR (0.50) | TSHRENPP2ESR2ALDH1A1HTT | |
| 1,3-Propanediol SCHEMBL4733793 | 0.88 | TSHR (0.41) | TSHRENPP2ESR2ALDH1A1HTT | |
| SCHEMBL16276509 | 0.86 | TSHR (0.46) | TSHRENPP2ESR2ALDH1A1HTT | |
| SCHEMBL7375093 | 0.80 | TSHR (0.40) | TSHRENPP2ESR2ALDH1A1GAA | |
| SCHEMBL21143321 | 0.80 | TSHR (0.40) | TSHRENPP2ESR2ALDH1A1GAA | |
| SCHEMBL3326323 | 0.80 | TSHR (0.45) | TSHRENPP2ESR2ALDH1A1CA1 | |
| SCHEMBL29383413 | 0.80 | TSHR (0.45) | TSHRENPP2ESR2ALDH1A1CA1 | |
| SCHEMBL19785358 | 0.79 | TSHR (0.39) | TSHRENPP2L3MBTL1PDK2NOTUM | |
| SCHEMBL561951 | 0.79 | NOTUM (0.39) | TSHRENPP2ESR2ALDH1A1CA1 | |
| SCHEMBL18340951 | 0.79 | TSHR (0.39) | TSHRENPP2ESR2ALDH1A1CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1968 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250194617-A1 | Materials and Methods for Extending Shelf-Life of Foods | JP LABORATORIES, INC. | 2025-06-19 | — | — | US | claimed |
| US-20250169514-A1 | Materials and Methods for Extending Shelf-Life of Foods | JP LABORATORIES, INC. | 2025-05-29 | — | — | US | claimed |
| CN-119674208-A | PEO-PAN-based polymer electrolyte membrane and preparation method and application thereof | 山东创鲁先进电池科技有限公司 | 2025-03-21 | — | — | CN | claimed |
| CN-115959993-B | Synthesis method of 2-aryl propionic acid compound | 山东中医药大学 | 2025-01-07 | — | — | CN | claimed |
| CN-118878402-A | Preparation method of trifluoromethyl ketone compound based on palladium catalysis of C-N bond cleavage | 大连理工大学 | 2024-11-01 | — | — | CN | claimed |
| CN-117352743-B | Sodium ion battery positive electrode material, preparation method thereof, positive electrode plate, battery and electricity utilization device | 宁德时代新能源科技股份有限公司 | 2024-04-12 | — | — | CN | claimed |
| CN-117865773-A | Preparation method of difluoromethyl aromatic compound based on palladium-catalyzed decarbonylation coupling | 大连理工大学 | 2024-04-12 | — | — | CN | claimed |
| CN-117352743-A | Sodium ion battery positive electrode material, preparation method thereof, positive electrode plate, battery and electricity utilization device | 宁德时代新能源科技股份有限公司 | 2024-01-05 | — | — | CN | claimed |
| EP-3704211-B1 | ORGANIC MOLECULES FOR USE IN OPTOELECTRONIC DEVICES | SAMSUNG DISPLAY CO LTD (KR) | 2023-12-27 | — | — | EP | claimed |
| US-20230380457-A1 | Materials and Methods for Extending Shelf-Life of Foods | JP LABORATORIES, INC. | 2023-11-30 | — | — | US | claimed |
| US-20080312451-A1 | Process For the Preparation of Sartan Derivatives and Intermediates Useful in Such Process | KRKA, D.D. NOVO MESTO (SK) | 2008-12-18 | — | — | US | claimed |
| WO-2008129077-A2 | CRYSTALLINE 1-(CYCLOHEXYLOXYCARBONYLOXY) ETHYL 1-((2'-CYANOBIPHENYL-4-YL)METHYL)-2-ETHOXY-1H-BENZO[D]IMIDAZOLE-7-CARBOXYLATE AND A PROCESS FOR ITS PREPARATION | KRKA, D.D. NOVO MESTO (SI) | 2008-10-30 | — | — | WO | claimed |
| US-7432278-B2 | Dicationic imidazo[1,2-a]pyridines and 5,6,7,8-tetrahydro-imidazo[1,2-a]pyridines as antiprotozoal agents | THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) | 2008-10-07 | — | — | US | claimed |
| EP-1931655-A2 | A PROCESS FOR THE PREPARATION OF SARTAN DERIVATIVES AND INTERMEDIATES USEFUL IN SUCH PROCESS | KRKA, D.D., Novo Mesto (SI) | 2008-06-18 | — | — | EP | claimed |
| WO-2008039827-A2 | POLYMER SYSTEMS FOR LUNG VOLUME REDUCTION THERAPY | AERIS THERAPEUTICS, INC. (US) | 2008-04-03 | — | — | WO | claimed |
| WO-2007039117-A2 | A PROCESS FOR THE PREPARATION OF SARTAN DERIVATIVES AND INTERMEDIATES USEFUL IN SUCH PROCESS | KRKA, D.D., NOVO, MESTO (SI) | 2007-04-12 | — | — | WO | claimed |
| EP-1764365-A1 | A process for the preparation of sartan derivates and intermediates useful in such process | KRKA, D.D., Novo Mesto (SI) | 2007-03-21 | — | — | EP | claimed |
| EP-1745045-A2 | NOVEL DICATIONIC IMIDAZO 1,2-a PYRIDINES AND 5,6,7,8-TE TRAHYDRO-IMIDAZO 1,2a PYRIDINES AS ANTIPROTOZOAL AGENTS | The University of North Carolina at Chapel Hill (US) | 2007-01-24 | — | — | EP | claimed |
| US-20050282853-A1 | Novel dicationic imidazo[1,2-a]pyridines and 5,6,7,8,-tetrahydro-imidazo[1,2,-a]pyridines as antiprotozoal agents | BOYKIN DAVID W | 2005-12-22 | — | — | US | claimed |
| WO-2005086808-A2 | NOVEL DICATIONIC IMIDAZO[1,2-a]PYRIDINES AND 5,6,7,8-TETRAHYDRO-IMIDAZO[1,2a]PYRIDINES AS ANTIPROTOZOAL AGENTS | THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) | 2005-09-22 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050282853-A1 | Novel dicationic imidazo[1,2-a]pyridines and 5,6,7,8,-tetrahydro-imidazo[1,2,-a]pyridines as antiprotozoal agents | PBRM1, QDPR, DHPS | TSHR 2689/4885ENPP2 3594/4885ESR2 4686/4885 |
| US-20080312451-A1 | Process For the Preparation of Sartan Derivatives and Intermediates Useful in Such Process | MC5R, NPY5R, ADRA1D | TSHR 70/4885ENPP2 2923/4885ESR2 1627/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.